Cancer Diagnostic Probe

Mohammad Abdolahad

Mohammad Abdolahad was born in Tehran, Iran, in 1982. He received his Ph.D. in Nanoelectronic Engineering from the University of Tehran in 2013. Immediately, he started teaching as an academic staff member in the College of Engineering, the School of Electrical and Computer Engineering. In the last few years, he has published more than 70 articles. He has 45 US patents in the field of cancer diagnosis and treatment devices. He has won many honors, including the Mustafa Award (2019), Selected Researcher of the Country (2019), Selected Young Researcher in 2017, etc.

The Impact of the CDP Device as a Surgeon Assistance System

The number of involved internal margins remained in the patient’s body despite Frozen and Permanent pathologies (evaluating tumor side margins) without considering CDP device’s results.

The number of involved internal margins remaining in the patient’s body using the CDP as a complementary tool along with Frozen and Permanent pathologies (evaluating tumor side margins).

The number of accurately diagnosed internal margins using the CDP device as a complementary tool along with Frozen and Permanent pathologies (evaluating tumor side).

The number of accurately diagnosed Internal margins by Frozen and Permanent pathology (evaluating tumor side margins) without considering CDP device’s results.

Scientific Advisors

: Prof. Akbari

: Prof. Abbasvandi

: Prof.miri

Checking the cavity-side margins during surgery for breast cancer patients is critical to ensure the definitive removal of suspicious and high-risk lesions with minimal damage to normal tissue. Remaining cancer cells in the breast causes re-surgeries and inevitable post-surgical treatments, which will have several side effects. Frozen pathology of tumor margins during surgery is a clinically accepted procedure to guide the surgeon to any need for re-excision. However, the time-consuming and expert dependent process of margin examination and false diagnostics, especially in neoadjuvant cases, are limitations of this procedure. CDP (Cancer Diagnosis Probe) system, has been introduced as a surgical assistant system in breast cancer surgery.
The new system reveals the cancerous cells in the internal margins (cavity-side margin) within a few millimeters in 40 seconds, using a needle sensor. This system has a clinical diagnostic classification matching with the pathological results of the tested tissues. The CDP response peaks are based on the classification of the pathological system (Ductal intraepithelial neoplasia (DIN), Lobular intraepithelial neoplasia (LIN), and Fibro epithelial lesion (FEL) (according to the latest reported revisions)).
The distinctive ability of CDP to detect cancer cells in the internal margins (after tumor dissection) has the sensitivity and selectivity of 97% and 94%, respectively.

Unique ability to non-invasively and real-time check intra-body margins after removing the mass during breast cancer surgery.
Immediate detection of margins infected with precancerous/cancerous cells not detected by frozen pathology and detected by CDP device with a diagnostic accuracy of over 93% during breast cancer surgery.
The ability to detect in real time the involvement of lymph nodes with cancer cells with a sensitivity of 92%.
Reduction of about 30% of the infected margins remaining in the body of patients with the help of CDP despite performing Frozen and Permanent pathology on the tumor margins, according to clinical trials conducted on more than 8000 margins inside the body in more than 600 Breast cancer patient for four years with the code: IRCT IRCT20190904044697N1 and IRCT20190904044697N3
The ability to evaluate tumors that are not identified before the operation and the surgeon faces them at once during the operation.
Real-time diagnosis capability in both neoadjuvant and non-neoadjuvant chemotherapy patients in all three models (margin-mass-lymph).
Helping to increase the prognosis and reduce the recurrence rate in breast cancer patients
Disposable head probe to prevent the transmission of contamination

: Dr. Fereshteh Abbasvandi
Breast Cancer Research

: Dr. Mohammad Esmaeil Akbari

Shahid Beheshti University of Medical Science

: Dr. Parisa Hosseinpour
Breast Pathologist

: Dr. Hengameh Saravani
Breast Cancer Research Center

: Dr. Nastaran Sadeghian
Breast Cancer Research Center

: Dr. Seyed Rouholah Miri
Assistant Professor of Surgery at Tehran & Alborz University of Medical Sciences

: Dr. Solmz Hashemi
Breast Oncology Fellow at Shahid Beheshti University of Medical Science

CDP in the Lymph Node Mode

Involved lymph node detection is also performed based on measuring the impedimetric properties associated with Fatty Acid Oxidation (FAO), which is the most dominant cancer cell metabolism in the lymph node environment.

Applying an LN headprobe on an auxiliary lymph node to detect LN involvement
Hematic view of a lymph node free of cancerous cells
The metabolism of cancer cells in the primary tumor site based on taking glucose from blood vessels (hypoxia glycolysis)
Schematic view of cancer cells spreading from the primary tumor site and invasion to a lymph node environment through lymphatic vessels
With the metabolic shift of cancer cells to Fatty Acid Oxidation (FAO)
Dimensions of an LN headprobe

Statistical Diagnostic Results of CDP in the margin and Lymph nodes

* Percentage reduction of the involved margins remaining in the patient’s body with the help of CDP despite performing Frozen-section and Permanent Pathology on tumor side margins (%)